This article is a commentary on AI regulation and does not describe a concrete new development, therefore it is not eligible for signal extraction.
By adopting more efficient biosimilar development guidelines, Celltrion can accelerate its pipeline and expand its market reach. This move strengthens its competitive position against other biosimilar developers and allows for more aggressive pricing strategies, potentially increasing market share in both established and emerging economies.
Celltrion to adopt new global biosimilar development guidelines
The changes are expected to reduce clinical development costs by up to 25%
The company plans to expand its biosimilar portfolio to 41 products by 2038
The changes are expected to reduce clinical development costs by up to 25%
The company plans to expand its biosimilar portfolio to 41 products by 2038
Sign in to save notes on signals.
Sign In